Usual request not to go slanging each other in this topic.
Biggest news by far is that a trial is being planned for ruxo in first-line treatment of pancreatic CA. You can blind all you want; it's pretty obvious how patients are doing overall in a study of a group expected to waste away and die in 2 months. Yeah, you follow up your failures as well as your successes, but not so quickly. Too soon to set off the fireworks, but you can order them.
Idea floated of allowing the label reference to clinical trials showing a survival benefit in MF is very attractive. No way will FDA allow a flat claim of live extension, but this might actually pass. Sales force still has to point to the reference, but it would multiply credibility.
No, nor would that be an early event. They said that they are planning a p2 in a first-line-of-treatment context.
Cancer drugs are often used off-label. Cancer drugs with dramatic early effects are often adopted widely before they can be fully tested (Avastin for breast CA is the dramatic bad example--gives a nice delay in radiologic progression, but when it was eventually possible to do a proper comparison, no survival benefit).
interesting that 110 is being developed as a jak 1, to see how it compares to the jak 1,2 that are on, the market and in the development stage, however could this be a drug that bites the hand that feeds you? not that there is a wish for poor results on 110, but good results can be problematic